GeneLink Inc.
(Public, OTC:GNLK)
First and foremost lets get some things out of the way as we know most of you have been awaiting this company profile for quite some time. We have been busy as a team upgrading the website on all fronts, and this weekend was no exception to the fact, however, unforeseen events causing malfunctions to our database led to the delay of this much anticipated company review. That being said, lets get down to business.
For those who just love financials, lets get this out of the way quickly so we can get into some more interesting topics. The company was Ranked Number 92 Fastest Growing Company in North America on Deloitte’s 2009 Technology Fast 500TM. GeneLink experienced 1,991 percent growth during this period., 2004-2009.
“Being named to the Deloitte 500 is an outstanding achievement”, said Monte Taylor, GeneLink CEO. “Substantially all of GeneLink`s revenue commenced with the launch of GeneWize Life Sciences, Inc. in the third quarter of 2008 and was based on roughly a half a year of revenue producing operations. Revenue for 2009 has already exceeded fiscal year 2008 and, assuming current trends at GeneWize continue, 2010 revenue should be even greater. As we continue to expand our science, product offerings, and the scope of our marketing efforts, we look forward to future growth.”
Products Target Market: 1+ Trillion Dollars
Patents: 20+ Including On The DNA Collection System
Stage: High Growth, Young Company
This company we are profiling is much more than the simplicity behind it being another stock market play. It is food for thought, a closer look at the future, and an investment in what could be the “Next Monster Company” as dubbed by the company’s management and several other industry experts.
Following the Human Genome Project (HGP) and the successful mapping of the human DNA which was completed in 2003. Many new capabilities once thought out of our reach have become feasible, making the impossible, possible.
HGP’s Impact On Medicine
All diseases have a genetic component, whether inherited or resulting from the body’s response to environmental stresses like viruses or toxins. The successes of the HGP have even enabled researchers to pinpoint errors in genes–the smallest units of heredity–that cause or contribute to disease.
The ultimate goal is to use this information to develop new ways to treat, cure, or even prevent the thousands of diseases that afflict humankind. But the road from gene identification to effective treatments is long and fraught with challenges. In the meantime, biotechnology companies are racing ahead with commercialization by designing diagnostic tests to detect errant genes in people suspected of having particular diseases or of being at risk for developing them.
An increasing number of gene tests are becoming available commercially, although the scientific community continues to debate the best way to deliver them to the public and medical communities that are often unaware of their scientific and social implications. While some of these tests have greatly improved and even saved lives, scientists remain unsure of how to interpret many of them. Also, patients taking the tests face significant risks of jeopardizing their employment or insurance status*. And because genetic information is shared, these risks can extend beyond them to their family members as well.
Explorations into the function of each human gene–a major challenge extending far into the 21st century –will shed light on how faulty genes play a role in disease causation. With this knowledge, commercial efforts are shifting away from diagnostics and toward developing a new generation of therapeutics based on genes. Drug design is being revolutionized as researchers create new classes of medicines based on a reasoned approach to the use of information on gene sequence and protein structure function rather than the traditional trial-and-error method. Drugs targeted to specific sites in the body promise to have fewer side effects than many of today’s medicines.
The rest of this article is available to premium members only.
Login or Become a member
